Pharma BD Deal Intelligence
Servier to acquire Day One maker of pediatric cancer drug tovorafenib for $2.5B at 68 percent premium to strengthen its rare oncology leadership position.
Servier is acquiring Day One Biopharmaceuticals for $2.5 billion, making it the French pharmaceutical company's largest acquisition to date. Day One markets…
Servier's 68-86% premium signals strategic prioritization over financial restraint, particularly given tovorafenib's FDA approval, positive EU regulatory…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Servier acquired Day One Biopharmaceuticals for approximately $2.5 billion ($21.50 per share in cash, a ~68% premium), with the transaction completed on April 23, 2026 following expiration of the tender offer on April 22, 2026 and a subsequent second-step merger; Day One was delisted from Nasdaq and became a wholly owned subsidiary of Servier. The deal gives Servier Ojemda (tovorafenib), an oral brain-penetrant RAF kinase inhibitor approved in the US for pediatric low-grade glioma and under EU review, complementing Servier's existing glioma portfolio anchored by Voranigo (vorasidenib).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. (this deal) | 2026 | $2.5B | 75 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Black Diamond Therapeutics, Inc. | 2025 | $780M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2026 deals · Servier Pharmaceuticals LLC deals · Oncology deals